July 16, 2010 – A new extracellular matrix (ECM) biomaterial device recently received a CE mark, meaning it can now be marketed in European Union countries. The CorMatrix ECM for Cardiac Tissue Repair from CorMatrix Cardiovascular harnesses the body’s innate ability to repair damaged cardiovascular tissue.

July 15, 2010 -- W. L. Gore and Associates recently announced that it has received the European CE mark approval for the 25 cm Gore Viabahn Endoprosthesis with Propaten Bioactive Surface. The Gore device is the longest length stent-graft available, designed to cover more of the lesion in the superficial femoral artery (SFA) potentially reducing the need for multiple devices.

July 15, 2010 – The first patient has enrolled in the Retrieve 2 U.S. trial, which will evaluate the safety and efficacy of Crux Biomedical's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter that is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE).

July 14, 2010 – The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases

July 14, 2010 – Medtronic Inc. recently announced it has received CE (Conformité Européenne) Mark for the Ensura MRI SureScan pacing system. Ensura MRI is the company’s new option in a portfolio of devices from Medtronic that have been designed, tested and approved for use with MRI machines.

July 14, 2010 – A Belgian biotechnology company recently announced positive safety data and preliminary efficacy results from a clinical trial of its new stem cell therapy for heart failure.

July 13, 2010 – A new analysis from the American College of Cardiology Foundation’s National Cardiovascular Data Registry (NCDR) shows that hospitals across the country are making improvements in the care of patients who have a heart attack or undergo percutaneous coronary intervention (PCI) procedures to unblock clogged coronary arteries.

July 13, 2010 – AstraZeneca recently announced that the U.S. District Court has found that the substance patent protecting Crestor is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

July 13, 2010 – A new meta-analysis of five implantable cardioverter-defibrillator (ICD) studies shows a smaller impact of sudden cardiac death (SCD) on overall mortality in women.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now